NYSE:AGNAllergan Stock Price, Forecast & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 10 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allergan.

Allergan is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Allergan.

Allergan plc (NYSE:AGN) posted its quarterly earnings results on Monday, February, 10th. The company reported $5.22 earnings per share for the quarter, topping the Zacks' consensus estimate of $4.57 by $0.65. The firm had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.09 billion. Allergan had a negative net margin of 15.44% and a positive return on equity of 8.46%. The business's revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.29 earnings per share. View Allergan's earnings history.

Allergan declared a quarterly dividend on Wednesday, March 18th. Investors of record on Thursday, April 16th will be paid a dividend of $0.74 per share on Monday, June 15th. This represents a $2.96 annualized dividend and a yield of ∞. The ex-dividend date is Wednesday, April 15th. View Allergan's dividend history.

Allergan declared that its Board of Directors has initiated a share buyback plan on Tuesday, January 29th 2019, which allows the company to buyback $2,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to buy up to 4.1% of its shares through open market purchases. Shares buyback plans are usually an indication that the company's leadership believes its stock is undervalued.

10 analysts have issued 1 year price targets for Allergan's stock. Their forecasts range from $165.00 to $203.00. On average, they expect Allergan's stock price to reach $184.89 in the next twelve months. View analysts' price targets for Allergan.

Media stories about AGN stock have trended negative on Monday, InfoTrie reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Allergan earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Allergan.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan has a market capitalization of $0.00 and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis. Allergan employs 17,400 workers across the globe.

The official website for Allergan is www.allergan.com.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]